Angiographic Surrogate End Points in Drug-Eluting Stent Trials
- 31 December 2007
- journal article
- research article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 51 (1) , 23-32
- https://doi.org/10.1016/j.jacc.2007.07.084
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Impact of Routine Angiographic Follow-Up on the Clinical Benefits of Paclitaxel-Eluting Stents: Results From the TAXUS-IV TrialJournal of the American College of Cardiology, 2006
- Robustness of Late Lumen Loss in Discriminating Drug-Eluting Stents Across Variable Observational and Randomized TrialsCirculation, 2005
- Late Loss in Lumen Diameter and Binary Restenosis for Drug-Eluting Stent ComparisonCirculation, 2005
- Relationship between angiographic late loss and target lesion revascularization after coronary stent implantationJournal of the American College of Cardiology, 2005
- Relationship of Late Loss in Lumen Diameter to Coronary Restenosis in Sirolimus-Eluting StentsCirculation, 2005
- Comparison of Late Luminal Loss Response Pattern After Sirolimus-Eluting Stent Implantation or Conventional StentingCirculation, 2004
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine, 2003
- Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS)The Lancet, 2003
- A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary RevascularizationNew England Journal of Medicine, 2002
- Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)The Lancet, 1998